Schedule III Is Just the Start: What 2026 Holds for Cannabis

Immediate Impact: The End of Section 280E 

The most immediate impact is relief from Internal Revenue Code Section 280E. Under Schedule I, cannabis businesses have been prohibited from deducting ordinary business expenses, leading to effective tax rates often exceeding 70%.

With the transition to Schedule III, state-compliant cannabis businesses are expected to become exempt from Section 280E, pending final implementation and IRS guidance. This allows for standard corporate tax deductions, significantly improving the liquidity and reinvestment capabilities of the sector. However, the application of this relief to businesses operating solely in the recreational (adult-use) sector is still subject to further clarification from the Department of the Treasury.

The June 29 Administrative Hearings 

A critical milestone in this roadmap is a series of expedited administrative hearings scheduled for June 29, 2026. These proceedings, overseen by the Drug Enforcement Administration (DEA), are designed to address the “Adult-Use Gap.”

The hearings will evaluate whether the findings used to justify the rescheduling of medical cannabis—namely its “currently accepted medical use”—can be extended to cover the entire botanical plant regardless of the end-user’s intent. The Department of Justice has signaled a desire to harmonize these regulations by mid-July 2026 to avoid a fractured federal enforcement policy between medical and recreational programs.

The “Hemp Paradox” and the 2018 Farm Bill 

The reclassification of marijuana creates a regulatory divergence from hemp. As marijuana becomes a Schedule III controlled substance, hemp remains federally “descheduled” under the 2018 Farm Bill. 

However, upcoming revisions to the Farm Bill seek to address the “loophole” regarding hemp-derived intoxicants (such as Delta-8 THC). Operators should monitor these legislative changes closely, as the federal government may attempt to bring high-potency hemp products under tighter regulation or restrict them entirely to ensure a single, regulated market for THC products. 

Federal vs. State Reality 

Despite these changes, it is important to note that Schedule III is not federal legalization. Cannabis remains a federally controlled substance. 

• Banking: While the SAFE/SAFER Banking Act remains the primary goal for full financial integration, Schedule III may reduce perceived regulatory and reputational risk for Tier 1 banks.
• Criminal Law: Federal penalties for the unauthorized distribution of Schedule III substances are lower than those for Schedule I, but the activity remains illegal outside of state-regulated systems.

FDA’s Role: A Sleeping Giant Awakens

One of the most consequential (but still uncertain) implications of rescheduling is the potential involvement of the U.S. Food and Drug Administration. Under Schedule III, cannabis would sit alongside substances that are typically subject to FDA oversight, particularly when marketed with therapeutic claims.

This raises the possibility of increased federal scrutiny over product standards, labeling, manufacturing practices, and clinical validation. While the FDA has historically taken a limited role in state-legal cannabis markets, rescheduling could create pressure for a more formal regulatory framework. 

Interstate Commerce: The Next Legal Battleground

The question of interstate commerce remains another unresolved aspect of the post-rescheduling landscape. While moving cannabis to Schedule III may ease certain federal restrictions, it does not automatically establish a legal pathway for cross-state trade.

At present, state markets operate in isolation, with strict controls on production and distribution within their borders. Whether federal authorities will permit or facilitate interstate cannabis commerce—either through legislative reform or administrative guidance—remains unclear. Until a cohesive framework emerges, operators should assume that state-by-state silos will persist, limiting economies of scale and complicating national expansion strategies.

Other Implications: Pharma, Trade, and Timeline Uncertainty

Beyond taxation and compliance, rescheduling introduces several broader structural questions:

• Pharmaceutical vs. State Markets: As cannabis gains formal medical recognition, there may be increased emphasis on FDA-approved, prescription-based products overseen by the U.S. Food and Drug Administration. This could create friction with existing dispensary models operating outside traditional drug approval pathways.
• International Trade: Schedule III status may shift perceptions, but global cannabis trade remains constrained by international treaty obligations and fragmented import/export rules, limiting near-term expansion.
• Timeline Uncertainty: Implementation is unlikely to be linear. Administrative proceedings, legal challenges, and agency rulemaking could delay or reshape key aspects of the transition.

Final Thoughts 

Schedule III appears to change everything—and yet, at the same time, not enough. The move is better understood as an administrative pivot rather than full deregulation. Much will depend on the upcoming June hearings, particularly for the adult-use sector. Stakeholders should focus on compliance and tax restructuring as the primary advantages of this new era.

Read more from Soft Secrets:

• US Drops Cannabis from Most Dangerous Drug Class
• 5 U.S. Cannabis Stock Markets to Invest in This Year
• Senator Cory Booker: Marijuana is Safer Than McDonald’s French Fries

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or medical advice. The regulatory environment regarding cannabis in the United States is subject to change. Readers should consult with legal counsel or tax professionals regarding specific business operations.